Paloma Moreno-Moreno

Paloma Moreno-Moreno

Auto-generated profile, based on publicly available information

Paloma Moreno-Moreno

Endocrinology and Nutrition Department, Reina Sofía University Hospital, 14004 Córdoba, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
MVMari C Vázquez-Borrego
Mari C Vázquez-Borrego
Antonio Carlos Fuentes-FayosAntonio Carlos Fuentes-Fayos
Antonio Carlos Fuentes-Fayos
AHAura D Herrera-Martínez
Aura D Herrera-Martínez
FLFernando L-López
Fernando L-López
AIAlejandro Ibáñez-Costa
Alejandro Ibáñez-Costa
Raul LuqueRaul Luque
Raul Luque
Context Pituitary neuroendocrine tumors (PitNETs) comprise a commonly underestimated pathology in terms of incidence and associated morbimortality. Currently, an appreciable subset of patients is resistant or poorly responsive to the main current medical treatments [i.e. somatostatin-analogues (SSAs)/dopamine-agonists]. Thus, development/optimization of novel/available medical therapies is necessary. Biguanides (metformin/buformin/phenformin) are antidiabetic drugs that exert antitumoral actions in several tumor types, but their pharmacological effects on PitNETs are poorly known. Objective We aimed to explore the direct effects of biguanides on key functions (cell-viability/hormone-release/apoptosis/signaling-pathways) in primary cell-cultures from human PitNETs and cell-lines. Additionally, we evaluated the combination of metformin with SSAs on cell-viability and hormone secretion. Design A total of 13 corticotropinomas, 13 somatotropinomas, 13 non-functioning PitNETs, 3 prolactinomas and two tumoral pituitary cell-lines (AtT-20 and GH3) were used to evaluate the direct effects of biguanides on cell-viability, hormone-release, apoptosis and signaling-pathways. Results Biguanides reduced cell-viability in all PitNETs and cell-lines (being phenformin the most effective biguanide), and increased apoptosis in somatotropinomas. Moreover, buformin and phenformin, but not metformin, reduced hormone secretion in a cell-type specific manner. Combination metformin-SSAs therapy did not enhance SSAs monotherapy effectiveness. Effects of biguanides on PitNETs could involve the modulation of AMPK-dependent ([Ca2+]i, PI3K/Akt) and independent (MAPK) mechanisms. Conclusion Altogether, our data unveil clear antitumoral effects of biguanides on PitNET cells, opening new avenues to explore their potential as drugs to treat these pathologies.

18 April 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MAMaría R. Alhambra-Expósito
María R. Alhambra-Expósito
AIAlejandro Ibáñez-Costa
Alejandro Ibáñez-Costa
PMPaloma Moreno-Moreno
Paloma Moreno-Moreno
EREsther Rivero-Cortés
Esther Rivero-Cortés
MVMari C. Vázquez-Borrego
Mari C. Vázquez-Borrego
Raul LuqueRaul Luque
Raul Luque
Acromegaly is a rare but severe disease, originated in 95% of cases by a growth hormone-secreting adenoma (somatotropinoma) in the pituitary. Magnetic resonance imaging (MRI) is a non-invasive technique used for the diagnosis and prognosis of pituitary tumours. The aim of this study was to determine whether the use of T2-weighted signal intensity at MRI could help to improve the characterisation of somatotropinomas, by analysing its relationship with clinical/molecular features. An observational study was implemented in a cohort of 22 patients (mean age = 42.1 ± 17.2 years; 59% women; 95% size>10 mm). Suprasellar-extended somatotropinomas presented larger diameters vs. non-extended tumours. T2-imaging revealed that 59% of tumours were hyperintense and 41% isointense adenomas, wherein hyperintense were more invasive (according to Knosp-score) than isointense adenomas. A higher proportion of hyperintense somatotropinomas presented extrasellar-growth, suprasellar-growth and invasion of the cavernous sinus compared to isointense adenomas. Interestingly, somatostatin receptor-3 and dopamine receptor-5 (DRD5) expression levels were associated with extrasellar and/or suprasellar extension. Additionally, DRD5 was also higher in hyperintense adenomas and its expression was directly correlated with Knosp-score and with tumour diameter. Hence, T2-weighted MRI on somatotropinomas represents a potential tool to refine their diagnosis and prognosis, and could support the election of preoperative treatment, when required.

3 October 2016 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
PMPaloma Moreno-Moreno
Paloma Moreno-Moreno
MAMaría Rosa Alhambra-Expósito
María Rosa Alhambra-Expósito
AHAura D. Herrera-Martinez
Aura D. Herrera-Martinez
RPRafel Palomares-Ortega
Rafel Palomares-Ortega
LZLuis Zurera-Tendero
Luis Zurera-Tendero
MGMaría Angeles Gálvez-Moreno
María Angeles Gálvez-Moreno
Objective. The aim of this study was to assess the utility of arterial calcium stimulation with hepatic venous sampling (ASVS) in the localization diagnosis of endogenous hyperinsulinism.Patients and Methods. A retrospective descriptive study was performed including patients with endogenous hyperinsulinism who underwent ASVS. The histopathological diagnosis in patients who underwent a surgical procedure was used as the reference for the statistical study of the accuracy of this technique.Results. 30 patients were included with endogenous hyperinsulinism and nonconclusive imaging diagnosis was included. ASVS was performed in all cases. Surgery was performed in 20 cases. Insulinoma was removed in 19 patients; the location of all cases was detected in the ASVS. All cases of endogenous hyperinsulinism had a positive result for the ASVS, with this association being statistically significant (χ2=15.771;p<0.001). A good and statistically significant agreement was obtained between histopathologic diagnosis and ASVS results (K=0.518,p<0.001).Conclusions. ASVS is a useful procedure in the localization diagnosis of endogenous hyperinsulinism undetected by other imaging tests. This technique allows the localization of intrapancreatic insulinomas and represents useful tool for the diagnosis and surgical management of these tumors.

3 August 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
IMIRENE CABALLERO MATEOS
IRENE CABALLERO MATEOS
MLMaria Dolores Garcia de Lucas
Maria Dolores Garcia de Lucas
VDViyey Kishore Doulatram-Gamgaram
Viyey Kishore Doulatram-Gamgaram
PMPaloma Moreno-Moreno
Paloma Moreno-Moreno
AJAna Isabel Jimenez-Millan
Ana Isabel Jimenez-Millan
Cristobal Jesus Morales PortilloCristobal Jesus Morales Portillo
Cristobal Jesus Morales Portillo
Although, in randomized clinical trials, once-weekly subcutaneous semaglutide (OW s.c.) has demonstrated superior efficacy in comparison with placebo and active controls in terms of glycemic control and body weight reduction in patients with type 2 diabetes mellitus (T2DM), these results need to be confirmed in a real-world (RW) setting. An RW ambispective study (6 months retrospective and 6 months prospective) was conducted in 10 tertiary hospitals in Spain. We evaluated changes in HbA1c and body weight in patients with T2DM treated with semaglutide OW s.c. Additionally, we analyzed different subgroups of patients treated with semaglutide OW s.c. as an add-on to glucose-lowering therapy. A total of 752 patients with a mean age of 60.2 years, a mean HbA1c level of 8.5%, a mean body weight of 101.6 kg, and a mean T2DM duration of 10 years were included. At 12 months, compared with baseline, there was a mean difference of −2.1% in HbA1c levels (p < 0.001) and a mean difference of 9.2 kg in body weight (p < 0.001). Moreover, there were statistically significant differences (p < 0.001) between baseline and month 12 in both HbA1c and body weight in the four subgroups receiving semaglutide OW s.c. as an add-on to glucose-lowering therapy. Semaglutide OW s.c. was well tolerated, with gastrointestinal disorders being the most commonly reported side effects. In this RW study, 12 months of treatment with semaglutide OW s.c. in patients with T2DM was associated with significant and clinically relevant improvements in glycemic control and weight loss, regardless of the glucose-lowering therapy received, and the overall safety profile was positive.

31 January 2013 in Endocrinología y Nutrición
Verified
Journal Article
Closed access
MEMaría Rosa Alhambra Expósito
María Rosa Alhambra Expósito
MMMaría Ángeles Gálvez Moreno
María Ángeles Gálvez Moreno
PMPaloma Moreno Moreno
Paloma Moreno Moreno
ISInmaculada Prior Sánchez
Inmaculada Prior Sánchez
CJConcepción Muñoz Jiménez
Concepción Muñoz Jiménez
PLPedro Benito López
Pedro Benito López

1 March 2010 in Endocrinología y Nutrición
Verified
Journal Article
Closed access
PMPaloma Moreno Moreno
Paloma Moreno Moreno
CACarmen Gutiérrez Alcántara
Carmen Gutiérrez Alcántara
MMMaría del Carmen Muñoz-Villanueva
María del Carmen Muñoz-Villanueva
RORafael Palomares Ortega
Rafael Palomares Ortega
MJMaría del Sierra Corpas Jiménez
María del Sierra Corpas Jiménez
PLPedro Benito López
Pedro Benito López